Condition: Angina (Stable) · CAD - Coronary Artery Disease · Unstable Angina · Sponsor: Advanced NanoTherapies
The study objectives are: 1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease. 2. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary de novo lesions \<3.00 mm in diameter in patients with symptomatic coronary artery disease.
This description comes directly from the study's public registry record.
Marwan Berrada-Sounni · (415) 517-0867 · mberrada@advnanot.com
Always discuss trial participation with your own doctor first.
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| Hospital Universitario Marques de Valdecilla | Santander, Spain | Recruiting |
| Hospital Alvaro Cunqueiro | Vigo, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07368933